Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.16) by 37.93 percent. The company reported quarterly sales of $134.00 million which beat the analyst consensus estimate of $130.13 million by 2.97 percent. This is a 6.94 percent decrease over sales of $144.00 million the same period last year.